Telomir-1 selectively kills triple-negative breast cancer cells in lab studies

Telomir Pharmaceuticals, Inc.

Telomir-1 produced concentration-dependent reduction in TNBC cell survival; iron addition reversed effect, confirming iron-dependent mechanism.
Compound targets aggressive TNBC cells' metabolic reliance on iron, potentially sparing healthy tissue due to differing iron management.
Findings link Telomir-1's effect to Jumonji domain histone demethylases (KDM5A/B, KDM6B) involved in cancer aggression and therapy resistance.
Company plans to expand studies to pancreatic and leukemia models, and conduct animal studies ahead of IND submission.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.